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Antibody-afﬁnityBordetella pertussis (Bp) is the etiologic agent of pertussis or whooping cough, a highly contagious respiratory
disease occurring primarily in infants and young children. Although vaccine preventable, pertussis cases have
increased over the years leading researchers to re-evaluate vaccine control strategies. Since bacterial outer
membrane proteins, comprising the surfaceome, often play roles in pathogenesis and antibody-mediated im-
munity, three recent Bp circulating isolates were examined using proteomics to identify any potential
changes in surface protein expression. Fractions enriched for outer membrane proteins were digested with
trypsin and the peptides analyzed by nano liquid chromatography-electrospray ionization-mass spectrome-
try (nLC-ESI-MS), followed by database analysis to elucidate the surfaceomes of our three Bp isolates. Fur-
thermore, a less labor intensive non-gel based antibody afﬁnity capture technology in conjunction with MS
was employed to assess each Bp strains' immunogenic outer membrane proteins. This novel technique is gen-
erally applicable allowing for the identiﬁcation of immunogenic surface expressed proteins on pertussis and
other pathogenic bacteria.
Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Bordetella pertussis (Bp) is the etiologic agent of pertussis or
whooping cough, a highly contagious respiratory disease occurring
primarily in infants and young children (Bordet and Gengou, 1906;
Singh and Lingappan, 2006). Current vaccines used in the United
States are acellular. They consist of three to ﬁve Bp proteins (Locht,
2008; Taylor and Fahm, 1999), including ﬁlamentous hemagglutinin
adhesin (FHA), pertactin (Prn), pertussis toxin (Ptx), and ﬁmbrae 2
and 3. These latter proteins are puriﬁed from Bp strains isolated
from the 1940s and 1950s. Many countries throughout the world,
however, continue to use whole-cell vaccines. Although pertussis is a
vaccine-preventable disease, theWorldHealth Organization (WHO) es-
timates that 30–50million cases per year occur worldwide, with ap-
proximately 300,000 deaths (http://www.cdc.gov/). In fact, pertussis
cases have increased over the years, leading researchers to reevaluate
vaccine control strategies. This resurgence in pertussis cases has oc-
curred globally (King et al., 2001; Das, 2002) and has occurred in popu-
lations or areas previously immunoprotected by vaccination. Although, MS-F50, Chamblee, Georgia
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C BY-NC-ND license.the cause for the observed increased disease incidence is not fully un-
derstood, possible contributing factors are better diagnostics and sur-
veillance, waning vaccine-induced immunity, suboptimal vaccine
formulation, and variation between circulating isolates and vaccine
strains (He and Mertsola, 2008; Matoo and Cherry, 2005; Bart et al.,
2010) which are all currently under investigation.
With the sequencing of many microbial pathogen genomes com-
plete (Parkhill et al., 2003) or underway, many researchers have re-
lied on functional genomics to translate the genetic “blueprint” of
an organism and to understand biological processes. But with con-
stantly advancing methods and technologies, the use of proteomic-
based strategies has emerged as an option to study cellular function.
In general, proteomics revolutionized in the mid 1970s (O'Farrell,
1975; Wilkins et al., 2007) is the analysis of an organism's proteome
or, in essence, its complete array of expressed genes or proteins.
Traditional proteomic approaches, such as one- (1D) or two-
dimensional (2D) gel electrophoresis (GE), are common technologies
to visualize and separate proteins based on molecular weight and/or
isolectric point (pI). 1D and 2D-GE, albeit fruitful, can be labor inten-
sive and not without technical challenges. For instance, 1D-GE cannot
sufﬁciently resolve very large proteins or complexes that generally
are membrane-afﬁliated and hydrophobic in nature. Also, small pro-
teins often expressed in low abundance may escape visual detection
dependent upon the rate of gel migration (Kustos et al., 2007).
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such as outer membrane proteins (OMPs) or surfaceomes can be
isolated by physical or chemical means, and further enriched using
sodium carbonate (Thein et al., 2010) followed by differential centri-
fugation. Fractionation reduces sample complexity and promotes
further examination by GE or mass spectrometry (MS). Nano liquid
chromatography-electrospray ionization tandem MS (nLC-ESI MS/MS)
is a powerful and sensitive analytical tool used to further elucidate
and characterize proteins in complex mixtures (Dworzanski and
Snyder, 2005; Han et al., 2008). Proteins can be proteolytically
cleaved by enzymes such as trypsin, generating peptides that are
ﬁrst separated by differential retention on the LC column then ion-
ized and separated based on their mass-to-charge ratio (m/z). The
proteins from which they originate are identiﬁed based on the com-
parison between MS/MS fragmentation patterns and protein data-
bases (Chen and Prama, 2008).
Over the years, gel-based strategies in parallel with MS have been
used with great success in the characterization of bacterial surfa-
ceomes (surface membrane fraction). For example, Somner et al.
(2010) performed a comparative surfaceome analysis of pathogenic
enterotoxigenic Escherichia coli (ETEC) and commensal strains using
gel and MS-based proteomic approaches. In addition, nLC-ESI MS/MS
analysis was used to proﬁle the surfaceome of four genetically distinct
Staphylococcus aureus strains (Dreisbach et al., 2010). Thein et al.
(2010) evaluated the efﬁciency of multiple surfaceome isolations
using nLC-ESI MS/MS, GE, and immunoblotting methodologies for
OMP identiﬁcation of various gram negative bacteria, including Pseudo-
monas aeruginosa. And Jabbour et al. (2010) performed a high-
throughput proteomics study using nLC-ESI MS/MS to identify cellular
proteins from pathogenic E. coli 0157:H7 and Yersinia pestis. Lastly,
Bottero et al. (2007) described a procedure for the enrichment
of Bp outer membrane proteins (OMPs) followed by protein identi-
ﬁcation using GE-associated mass spectrometric technologies and
database search analysis as the basis for novel pertussis vaccine
development.
Bp, a gram-negative organism, contains outer and cytoplasmic (or
inner) membranes separated by a periplasmic space. Proteins embed-
ded within the membrane and surface-exposed are of biological im-
portance. These bacterial proteins act as front-line barriers to the
hosts' antibody-mediated cellular environment. They contain possi-
ble virulence factors, and they play a role in the attachment to host
cells as well as in the transport of nutrients into the bacteria needed
for growth and survival (Poolman et al., 1990; van den Berg et al.,
1999; Kustos et al., 2007; Lee et al., 2008). Thus, further examination
of this subproteome (in particular for clinical pathogens) by GE or ad-
vanced technologies such as MS, would be fruitful for the develop-
ment of novel diagnostics, strain comparison, or potentially for
improved vaccine development.
In this study, a comparative qualitative proteomic assessment of
three clinical Bp strains isolated in the United States and the well-
typed acellular and whole-cell vaccine strain Tohama I was investi-
gated. Since changes in OMP expression might affect several bacterial
functions such as adherence and pathogenesis with possible implica-
tions on host cellular immunity (Kustos et al., 2007; Jabbour et al.,
2010), we examined the surfaceome and immunoproteome (i.e., an-
tigenic proteins that invoke an immune response). Protein proﬁles
were generated using a multi-combinatorial approach of 1D-GE
and/or direct nLC-ESI MS/MS tryptic peptide detection and OMP iden-
tiﬁcation via database search analysis. Additionally, immunoblot-
associated MS analysis and a novel approach using antibody afﬁnity
magnetic-bead-capture coupled to MS were used to identify Bp immu-
noreactive proteins. This antibody afﬁnity, magnetic-bead-capture
technique proved to be a labor-saving strategy that assisted in the
quick assessment of Bp protein immunoreactivity. This strategy shows
great promise as an expeditious approach – applicable to a broad spec-
trum of organisms – to identify surface-expressed antigens which, oncedetected and identiﬁed, could be used for strain comparisons and for
improved diagnostics.
2. Materials and methods
Fig. 1 is a ﬂow diagram schematically summating the core meth-
odologies used in this study.
2.1. Reagents
All reagents and media not vendor-speciﬁed were prepared at the
Centers for Disease Control and Prevention (CDC) Core Facility. In ad-
dition, chemicals used in experimentation were obtained from either
Sigma-Aldrich Chemical Company (St. Louis, MO, USA) or Fisher Sci-
entiﬁc (Pittsburg, PA, USA) as noted.
2.2. Bacterial strains
Four Bp strains, Tohama I (T) and three clinical isolates designated
by CDC as C056 (C), D946 (D) and F656 (F) were used in the proteo-
mic comparison (Table 1). T, ﬁrst isolated in Japan in 1954, is a well-
characterized and completely sequenced Bp strain that has been used
as the basis of vaccines in many countries for several years (Advani
et al., 2004). By pulse-ﬁeld gel electrophoresis (PFGE) analysis, it is
characterized as type II and possesses the pertactin 1 (prnA1) and
pertussis toxin (ptxS1B) genotype typical of prevaccine-era isolates
(Advani et al., 2004; van Loo et al., 2002; Litt et al., 2009). Strain C
was isolated in Minnesota in 1998, has a PFGE CDC type 10 (Hardwick
et al., 2002), and a prnA2, ptxS1A genotype common among currently
circulating isolates (Litt et al., 2009). The D strain, a clinical isolate iden-
tiﬁed in Georgia in 2002, has a PFGE CDC 21, prnA1 and ptxS1A geno-
type. It has shown resistance to the antibiotic erythromycin. Lastly,
the F strain (PFGE CDC 206, prnA2, ptxS1A) was isolated from a clinical
case in 2007 in the Virgin Islands.
2.3. Bacterial cell culture
T, C, D, and F were plated on Bordet-Gengou agar and incubated at
35 °C with 5% CO2 for 4 days (Hulbert and Cotter, 2009). The bacteria
were subsequently subcultured into Modiﬁed Stainer-Schulte (MSS)
media at 35 °C, with aeration at 200 rpm in a Beckman-Coulter shaker
(Beckman-Coulter, Brea, CA, USA) until an optical 1.0 density was
reached. The bacterial strains were then pelleted from MSS by centri-
fugation at 8000×g for 30 min (min) at 4 °C. The pellets were washed
two times in distilled water (dH2O) and stored at −70 °C for further
use.
2.4. Enriched membrane fraction collection
Enrichedmembrane fractions (EMFs)were collected as previously de-
scribed (Molloy, 2008) with the following modiﬁcations. Brieﬂy, cell pel-
lets of Bp isolates were allowed to thaw gently on ice. The pellets were
French-pressed at 16,000 psi in 5 ml of a 50-mMTris–HCl (pH 8.0) buffer
containing a protease inhibitor cocktail added at the manufacturer's rec-
ommendation (GE Healthcare, Piscataway, NJ, USA), and 25U of benzo-
nase to rupture bacterial cells. The lysates were centrifuged (8000×g,
20 min, 4 °C) to remove unbroken cells, and the supernatant containing
the total extracted proteome was retained. 50 ml of ice-cold sodium car-
bonate (pH 11.0) was added to 5 ml of each bacterial supernatant. The
mixture was stirred gently at 4 °C for 2 h. The sodium carbonate
infused-supernatants were subjected to ultracentrifugation (Beckman-
Coulter) (115,000×g, 60 min, 4 °C) to enrich for amembraneprotein frac-
tion. The pellets containing the EMFs were washed in a 50 mM Tris–HCl
buffer (pH 8.0) and ultracentrifuged twice (115,000×g, 30 min, 4 °C) to
remove the enrichment buffer. The ﬁnal EMFs were solubilized in 1 ml
of solubilization buffer containing 7 M urea, 2 M thiourea, 2% CHAPS,
Fig. 1. Flow diagram of core methodologies used in the proteomic study. Red Asterisk (*) indicates the mouse sera was used for the immunoblot analysis and immunoprecipitation.
Black asterisk (*) indicates human convalescent sera was used for the immunoprecipitation.
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tion of 0.5% bromophenol blue to visually assess the integrity of protein
isolation. Protein concentrations of the samples were determined using
a 2D-Quant Kit (GE Healthcare), and the samples were aliquoted and fro-
zen at−20 °C until further use.2.5. B. pertussis immune sera
Three-week-old female BALB/C mice were initially injected intra-
peritoneally (i.p.) with 1×109 colony forming units (cfu) of T, C, D,
or F suspended in 10 μl of physiological saline (pH 7.2). Before injec-
tion, strains were cobalt-irradiated using 5×106 γ RAD to inhibit bac-
terial replication and infectivity, while preserving bacterial surface
structures. The process was repeated 2 weeks later, every 2 weeks
thereafter, with three separate i.p. immunizations of similar dosage
for 6 weeks. At this time, mice were euthanized according to AALAC
and IACUC standards and the Bp immune sera generated from each
strain were collected from blood. The collected serum was aliquoted
and stored at−70 °C until use. Additionally, a serum pool composed
of sera drawn from convalescent pertussis human patients obtained
from the CDC Pertussis Laboratory was used in this analysis. This
pool is the Pertussis Laboratory ELISA standard reference seraTable 1
Genomic proﬁles of Bordetella pertussis (Bp) strains assessed in the study. Abbrevia-
tions: T — Tohama I, C — C056, D — D946 and F — F656; USA — United States of Amer-
ica; CDC — Centers for Disease Control and Prevention; PFGE — pulse ﬁeld gel
electrophoresis; Prn — pertactin; Ptx — pertussis toxin.
Strain Isolation location (Year) PFGE Pertactin Pertussis toxin
T Japan (1954) Type II prnA1 ptxS1B
C Minnesota, USA (1998) CDC type I0 prnA2 ptxS1A
D Georgia, USA (2002) CDC type 21 prnA1 ptxS1A
F Virgin Islands, USA (2007) CDC type 206 prnA2 ptxS1Aacquired in accordance with CDC Institutional Review Board stan-
dards and regulations.
2.6. 1D sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblot analysis of B. pertussis EMF
Unless speciﬁed, materials, antibodies, and procedures for GE and im-
munoblot analysiswere obtained fromBio-Rad (Hercules, CA, USA). 10 μg
of total EMF proteins from each strain was suspended in Laemmli sample
buffer and electrophoresed on 12.5% SDS-PAGE gels following standard
protocols (Laemmli, 1970). To visualize separated proteins, gels were
stained using the hot coomassie blue staining protocol. EMF proteins
were electroblotted (Towbin et al., 1979) onto polyvinylidene ﬂuoride
(PVDF) membranes for 1 h and probed with either a primary Bp strain-
speciﬁc immune or preimmune (normal)mouse serum. Immunoreactive
bands were further probed with a secondary goat-anti-mouse horserad-
ish peroxidase-conjugated IgG antibody and subsequently visualized
with 1,4-benzenediamine dihydrochloride (Sigma-Aldrich).
2.7. PVDF on-membrane protein extraction
Protein extraction directly from blotted-PVDF membranes was
performed based on Bienvenut et al. (1999), but modiﬁed according-
ly. PVDF membrane bands containing EMF proteins from T and C as-
sociated with immunoreactivity were excised and destained with
50% methanol (500 μl) for 2 h at room temperature (RT). After
destaining, the supernatant was removed. The membrane pieces
were air dried, followed by the addition of 50 mM ammonium bicar-
bonate (NH4(CO3)2) digestion buffer in 30% acetonitrile (ACN) (Fish-
er Scientiﬁc). The protein-containing membrane pieces were then
incubated overnight (ON) with trypsin (0.1 μg/μl) (Promega Corpora-
tion, Carlsbad, CA, USA) at 37 °C. After digestion, the supernatant was
collected and the membranes were treated with 80% ACN to extract
the peptides and sonicated at level nine (Aquasonic™ model 150-
D)(VWR Scientiﬁc Products, Suwanee, GA) for 15 min. Following son-
ication, the extract was pooled with the previous supernatant, dried
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were prepared for nLC-ESI-MS/MS, in which peptides were sus-
pended in equal volumes of 0.1% formic acid.
2.8. EMF protein identiﬁcation
T, C, D, or F EMFs (10 μg) before direct proteolytic cleavage were
treated with 0.1% rapigest (RG) (Waters Corporation, Milford, MA,
USA) in NH4(CO3)2 digestion buffer at 100 °C for 5 min to denature
proteins. Upon cooling at RT, the samples were incubated ON with
trypsin (10 μg) (Promega) at 37 °C. After incubation, the RG was inac-
tivated in the presence of 1 M HCl for 30 min at 37 °C, and centrifuged
at 12,000×g for 15 min. The supernatant was removed and sus-
pended in equal volumes of 0.1% formic acid and analyzed by nLC-
ESI MS/MS. The data obtained represent two distinct biological prep-
arations, each performed in triplicate.
2.9. Immunoprecipitation studies using antibody afﬁnity magnetic bead
capture technology
Dynal beads (Invitrogen Corporation, Carlsbad, CA, USA) coated
with protein G for immunoglobulin (IgG) capture and subsequent
immunoprecipitaton (IP) of EMFs were used as per the manufacturer's
recommendation with the following changes. The Dynal beads (200 μl
per sample) were initially washed three times via resuspension in
800 μl phosphate citrate buffer (PCB), pH 5.0 (Sigma-Aldrich). Next,
the beads were resuspended in 800 μl PCB and incubated ON at 37 °C
in the presence of immune sera (100 μg total) from mice immunized
against T, C, D or F. We also prepared controls containing normal
mouse immune sera (100 μg total) and beads only. After incubation,
the beads were magnetically stabilized, the supernatant was removed,
and the beads were washed two times with 2 M triethanolamine, pH
8.2 (Sigma-Aldrich). This was to remove unbound antibodies and to
equilibrate the beads for antibody crosslinking. The immune-sera
bound beads were next cross-linked with 1 ml 20 mM dimethyl pime-
limidate (Sigma-Aldrich) in 2 M triethanolamine for 30 min at RT via
inversion. Following crosslinking, the beads were washed two times
in 800 μl phosphate buffer saline (PBS), pH 7.0 with 0.1% Tween 20
and further incubated with 800 μl TBE (Sigma-Aldrich) to reduce non-
speciﬁc (NS) protein binding. The beads were resuspended in 50 μl
dH2O. Then they were incubated at 37 °C ON in the presence of T, C,
D or F EMFs (10 μg) that corresponded with the bead-Ab source
strain (e.g., beads bound with T-speciﬁc IgG were incubated in the
presence of T-EMF). After magnetic stabilization, the beads were
washed via a mixer three times for 5 min with 100 μl PBS at RT to re-
move any unbound or NS-bound EMF proteins. The protein-bound
Ab-coupled complexes were resuspended in 50 μl NH4(CO3)2 diges-
tion buffer treated with 0.1% RG followed by ON trypsin (10 μg) di-
gestion at 37 °C.
Upon incubation, the IP complex was magnetically stabilized, and
the supernatant containing EMF tryptic peptides was transferred to a
fresh tube and dried via vacuum centrifugation to concentrate samples.
The RGwas inactivated and the samples prepared for nLC-ESIMS/MS, in
which peptides were suspended in equal volumes of 0.1% formic acid.
The data represent two biological preparations, each performed in du-
plicate. Simultaneously, Dynal beads were conjugated with pooled
human convalescent sera (100 μg total) resulting from Bp infection in
addition to normal human IgG (Interstate Blood Bank, Inc., Memphis,
TN, USA). The IgG bound-beads were incubated with T, C, D, or F EMF
(10 μg), and the samples were processed as described above.
2.10. Nano liquid chromatography electrospray ionization mass
spectrometry
Protein identiﬁcation was achieved by using nanoﬂow liquid chro-
matography (nano-LC), data-dependent tandem mass spectrometry,and database searching. A pulled-needle, fused silica capillary
(365 μm O.D. by 75 μm I.D.) (New Objective, Inc., Woburn, MA) was
packed with 10 cm of 5 μm Symmetry 300 reverse-phase packing ma-
terial (Waters Inc., Bedford, MA). Protein digests were loaded onto
the analytical column and separated by gradient elution using an
Eksigent 2D nanoLC system (Eksigent Technologies, Inc, Dublin, CA).
The mobile phase solvents consisted of (solvent A) 0.2% formic acid
(Thermo Scientiﬁc, Rockford, IL), 0.005% triﬂuoroacetic acid (Sigma-
Aldrich) in water (Burdick and Jackson, Muskegon, MI), and (solvent
B) 0.2% formic acid, 0.005% triﬂuoroacetic acid in acetonitrile (Burdick
and Jackson). The gradient ﬂow was set at 400 nl/min. The proﬁle
consisted of a hold at 5% B for 5 min followed by a ramp to 30% B
over 100 min, then a ramp up to 90% B in 5 min and a hold at 90%
for 2 min before returning to 5% B in 2 min and re-equilibration at
5% B for 20 min. After chromatography, peptides were introduced
into an LTQ Orbitrap tandem mass spectrometer (Thermo Scientiﬁc,
San Jose, CA). A 2.0 kV voltage was applied to the nano-LC column.
The mass spectrometer was programmed to perform data-dependent
acquisition by scanning the mass range from mass-to-charge (m/z)
400 to 1600 at a nominal resolution setting of 60,000 for parent ion ac-
quisition in the Orbitrap. Most tryptic peptides fall within the stated
m/z range and served as the basis for this selection. For MS/MS anal-
ysis the mass spectrometer chose the top 10 most intense ions with
two or more charges. Singly charged ions were rejected for MS/MS
as these ions are likely due to detergents or other sample additives.
In particular for a data-dependent acquisition, time is better utilized
acquiring for doubly and triply charged amino acids, which predom-
inantly have greater sequence speciﬁcity since they are larger pep-
tides and thus provide a higher likelihood in which to uniquely
identify a protein.
All tandem mass spectra were extracted from the raw data ﬁle
using Mascot Distiller (Matrix Science, London, UK; version 2.2.1.0)
and searched using Mascot (version 2.2.0). Mascot was set up to
search using the entire NCBInr database or a modiﬁed NCBInr data-
base created to search “Bordetella”- or “pertussis”- recognized pro-
teins in which trypsin is used as the digestion agent. Mascot was
searched with two missed cleavages, a fragment ion tolerance mass
of 0.80 Da, and a parent ion tolerance of 200 ppm, while oxidation
was selected as a variable modiﬁcation. Scaffold (Proteome Software,
Portland, OR) was used to validate MS/MS based peptide and protein
identiﬁcations.
Peptide identiﬁcations were accepted if they could be established
at greater than 95.0% probability as speciﬁed by the Peptide Prophet
algorithm (Keller et al., 2002). Protein identiﬁcations were accepted
if they could be established at greater than 99.0% probability and con-
tained at least two identiﬁed peptides (Nesvizhskii et al., 2003). With
these stringent parameters of Peptide Prophet and Protein Prophet
within the Scaffold software, the probability of a wrong assignment
is below 0.1%. PSORTb subcellular scores were used to predict and lo-
calize identiﬁed EMF proteins (http://www.psort.org/psortb/) (Yu
et al., 2010). Lastly, KEGG identiﬁers using NCBI Gi accession numbers
were employed to assign functions to each of the identiﬁed proteins
http://www.genome.jp/kegg/kegg3.html (Tefon et al., 2011).
3. Results
3.1. 1GE and immunoblot analysis of B. pertussis species EMFs
Carbonate-enriched EMF proteins were initially separated by 1D-
SDS-PAGE (1D-GE). This was to observe common and differential
banding patterns between the T-reference strain and clinical isolates
C, D, and F. Overall, similar protein proﬁles among the strains were
observed, with 1D-GE revealing slight differences and no unique pro-
tein banding patterns between the strains (Fig. 2). Subsequently, after
observing no major protein differences, we used classical immuno-
blotting approaches to assess the strain's ability to invoke an immune
Fig. 2. SDS-PAGE of Bp T, C, D, and F enriched membrane fractions (EMF). 10 μg of total
carbonate-extracted EMF proteins from each strain was suspended in Laemmli sample
buffer, electrophoresed on 12.5% SDS-PAGE gels, and stained using the hot coomassie
blue staining protocol. Abbreviation: T — Tohama I, C — C056, D — D946 and F —
F656; SDS-PAGE — sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Table 2B
Subcellular localization of identiﬁed Bp EMF proteins (** — Table 2A). PSORTb subcellular
scores were used to predict and localize the identiﬁed EMF proteins.
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strain-speciﬁc mouse antisera, showed comparable patterns of im-
munoreactivity between all four strains. Likewise, the similarity in
the immunoblot corresponded with the heavy banding patterns be-
tween 30 and 70 kDa observed in the stained gel (data not shown).
Collectively, the gel and immunoblot results indicate similarity in
the proteins expressed among these strains. And nominal differences
appeared between the immune responses seen in mice against T, C, D,
and F. Nevertheless, to delineate any signiﬁcant variability which was
not visually observable, a few major immunoreactive protein bands
from 30 to 35 and 40 to 45 kDa were analyzed for T and C. Peptides
extracted from tryptically digested, excised-PVDF membranes were
separated and analyzed using nLC-ESI-MS/MS. Database mining
revealed a few proteins in both the T and C highly immunoreactiveTable 2A
Summary of the total number of Bp enriched membrane fraction (EMF) proteins com-
monly and uniquely identiﬁed among the Bp strains assessed in the study. Numerical
values are based on a greater that 95% Scaffold protein identiﬁcation probability**. Ab-
breviations: T — Tohama I, C — C056, D — D946 and F — F656.





Strain combinations Total number of common proteins
T, C , D ,and F 163
T and C only 1
T and D only 3
T and F only 0
C and D only 0
C and F only 0
D and F only 0
T, C and D only 1
T, C and F only 5
T, D and F only 2
C, D and F only 3




F only 3bands. These included a 42-kDa outer membrane porin precursor
(OmpP), a 40-kDa outer membrane porin protein OmpQ (OmpQ),
and a 40-kDa putative exported protein. The C-EMF-probed excised
protein bands also identiﬁed a 33-kDa putative membrane protein.3.2. Direct surfaceome analysis of Bp EMFs using nLC-ESI-MS/MS
Although Bp EMF proteins were separated and visualized using
GE, and a few further identiﬁed by an on-membrane analysis in com-
bination with MS, a more direct and less time-consuming surfaceome
analysis was ultimately implemented.
RG-treated and trypsinized-EMFs from the four strains were ana-
lyzed directly using nLC-ESI MS/MS. This was followed by database
searching, in which 259, 249, 253, and 245 proteins were identiﬁed
for T, C, D and F, respectively. However, based on greater than 95%
Scaffold protein identiﬁcation and amino acid coverage probabilities,
193 total proteins among all four strains were further selected
(Table 2A). Moreover, using PSORTb subcellular localization scores, pro-
teins consideredmembrane (outer, periplasmic, or cytoplasmic) or found
in the cytoplasm accounted for 44% and 29%, respectively, of the total
“surfaceome” identiﬁed in this study. The remaining proteins classiﬁedTable 2C
Protein function of identiﬁed Bp EMF proteins (** — Table 2A). KEGG identiﬁers were
employed to assign functions to each of the identiﬁed EMF proteins.
Table 2D
Summary of Bp EMF proteins identiﬁed among Bp strains assessed in the study (** — Table 2A). NCBI Gi accession numbers were used to further compile information such as gene
identiﬁcation number, subcellular localization (PSORTb) and protein function (KEGG identiﬁers). Values noted represent percent amino acid coverage of the identiﬁed EMF protein.
(Number of unique peptides detected in parenthesis.). (^) indicates that identiﬁed proteins only had one unique detected tryptic peptide. No numerical value noted indicates that
the protein was not identiﬁed in the strain. Abbreviations: T— Tohama I, C— C056, D— D946 and F— F656; OM— outer membrane, CM— cytoplasmic membrane, C— cytoplasm, P
— periplasm, E — extracellular, M — membrane, U — unknown, Pu — putative, HP — hypothetical protein; DH (dehydrogenase), P-5-C-DH (pyrroline-5-carboxylate DH), SFP (su-





Location T C D F Function
30S ribosomal protein S2 NP_880161 BP1419 rpsB 28 C 28 (4) 23 (3) 21 (3) 23 (3) Translation
30S ribosomal protein S3 NP_882129 BP3619 rpsC 29 C 27 (4) 27 (4) 27 (5) 27 (4) Translation
50S ribosomal protein L16 NP_882130 BP3620 rplP 15 C 26 (3) 36 (4) 19 (2) 29 (3) Translation
50S ribosomal protein L18 NP_882141 BP3632 rplR 13 C 20 (2) 20 (2) 30 (3) 20 (2) Translation
50S ribosomal protein L2 NP_882126 BP3616 rplB 30 C 14 (3) 11 (2) 11 (2) 17 (3) Translation
50S ribosomal protein L5 NP_882137 BP3628 rplE 20 C 17 (3) 12 (2) 12 (2) 18 (3) Translation
50S ribosomal protein L6 NP_882140 BP3631 rplF 19 C 27 (3) 27 (3) 27 (3) 19 (2) Translation
2-Isopropylmalate synthase NP_879030 BP0131 leuA 62 U 6 (2) 14 (5) 8 (3) 11 (4) Metabolism
5-Meta^ NP_881170 BP2543 metA 84 U 1 (1) 4 (2) 4 (2) 4 (2) Metabolism
ABC transporter NP_879529 BP0697 U 29 CM 22 (3) 22 (3) 27 (4) 28 (4) Membrane transport
Acteyl-CoA carboxylase carboxyltransferase subunit
alpha
NP_880596 BP1910 accA 35 C 17 (4) 29 (6) 24 (5) 17 (4) Metabolism
Aconitate hydratase NP_880684 BP2014 acnA 99 C 5 (3) 5 (3) 3 (2) 4 (2) Metabolism
Acriﬂavine resistance protein B NP_879779 BP0985 acrB 116 CM 6 (4) 3 (2) 5 (3) 3 (2) Drug resistance
Adenylosuccinate lyase NP_881474 BP2890 purB 50 C 7 (3) 5 (2) 9 (3) 9 (3) Metabolism
Alanyl-tRNA synthetase NP_880538 BP1836 alaS 96 C 15 (10) 9 (6) 8 (6) 8 (5) Translation
ATP-dependent protease La NP_880488 BP1777 Ion 90 C 5 (4) 5 (3) 6 (4) 5 (3) Metabolism
Autotransporter NP_880953 BP2315 vag8 101 OM/E 24 (15) 37 (22) 28 (18) 38 (22) Transport
Autotransporter subtilisin-like protease CAC44081 U sphB1 114 OM/E 14 (9) 16 (9) 23 (15) 17 (10) Transport
Bifunctional aconitate hydratase 2/2-methylisocitrate
dehydratase
NP_880691 BP2021 acnB 95 C 8 (5) 6 (3) 9 (6) 6 (3) Metabolism
Bifunctional hemolysin-adenylate cyclase precursor NP_879578 BP0760 cyaA 188 E 8 (8) 18 (20) 10 (12) 14 (15) Metabolism
Capsular polysaccharide biosynthesis protein NP_880357 BP1629 wbpO 47 C 13 (3) 13 (3) 10 (2) 10 (2) Metabolism
Cell division protein NP_879861 BP1077 ftsH 69 CM 20 (9) 15 (6) 12 (6) 15 (7) Cell division
Cell division protein FtsA NP_881594 BP3019 ftsA 45 C 18 (5) 18 (5) 17 (5) 14 (4) Cell division
Chain A, structure of the membrane protein Fhac 2QDZ_A U U 61 OM 22 (6) 26 (8) 25 (8) 27 (9) Transport
Chaperonin GroEL NP_882014 BP3495 groEL 60 C 16 (5) 13 (5) 20 (8) 12 (5) RNA degradation
Competence lipoprotein NP_879922 BP1146 comL 29 OM 21 (4) 12 (2) 26 (5) 16 (3) Transport
Cytochrome C1 precursor NP_879155 BP0275 petC 31 U 34 (6) 24 (4) 13 (3) 29 (4) Metabolism
D-fructose-6-phosphate amidotransferase^ NP_879503 BP0666 glmS 67 C 7 (3) 4 (1) 10 (4) 8 (3) Metabolism
Dihydrolipoamide acetyltransferase^ NP_879904 BP1125 odhB 44 CM 3 (1) 24 (4) 19 (3) 11 (2) Metabolism
Dihydroorotate dehydrogenase 2 NP_881968 BP3442 pyrD 38 CM 21 (4) 18 (3) 18 (3) 13 (2) Metabolism
Dihydroxy-acid dehydratase NP_879169 BP0289 ilvD 68 C 7 (3) 5 (2) 5 (2) 5 (2) Metabolism
DNA gyrase subunit B NP_879342 BP0489 gyrB 90 C 4 (2) 7 (4) 3 (2) 5 (3) DNA synthesis
DNA topoisomerase III^ NP_879317 BP0460 topB 96 C 9 (5) 9 (5) 8 (4) 2 (1) DNA synthesis
DNA-directed RNA polymerase subunit beta NP_878932 BP0015 rpoB 151 C 3 (2) 7 (7) 5 (5) 4 (4) Metabolism
DNA-directed RNA polymerase subunit beta NP_878933 BP0016 rpoC 155 C 3 (3) 4 (4) 3 (4) 2 (2) Metabolism
Elongation factor G NP_882120 BP3610 fusA 77 C 26 (11) 24 (10) 13 (6) 20 (9) Translation
Elongation factor Tu NP_878925 BP0007 tuf 44 C 38 (9) 31 (7) 21 (5) 33 (8) Translation
Enoyl- (acyl carrier protein) reductase^ NP_881766 BP3215 fabL 29 CM 5 (1) 9 (2) 9 (2) 4 (1) Lipid metabolism
F0F1 ATP synthase subunit alpha^ NP_881828 BP3286 atpA 56 C 8 (3) 5 (2) 11 (4) 2 (1) Energy metabolism
F0F1 ATP synthase subunit B NP_881826 BP3284 atpF 17 CM 30 (4) 30 (4) 43 (6) 37 (5) Energy metabolism
F0F1 ATP synthase subunit beta NP_881830 BP3288 atpD 51 CM 17 (5) 23 (6) 7 (2) 15 (3) Energy metabolism
Filamentous hemagglutinin/adhesion NP_880571 BP1879 fhaB 394 OM 18 (43) 16 (37) 16 (38) 15 (34) Adherence
Glutamate synthase [NADPH] large chain precursor NP_882256 BP3753 qltb 174 C 7 (7) 3 (4) 2 (2) 6 (6) Amino acid metabolism
Guanosine-3′,5′-bis (diphosphate)
3′-pyrophosphohydrolase
NP_880309 BP1576 spoT 83 U 5 (3) 7 (4) 5 (3) 10 (6) Nucleotide metabolism
Histone protein NP_881561 BP2985 bpH1 19 C 18 (2) 18 (2) 18 (2) 18 (2) DNA synthesis
HlyD family secretion protein^ NP_882313 BP3815 hlyD 46 CM 10 (2) 5 (1) 13 (3) 10 (2) Signal transduction
Homoserine dehydrogenase^ NP_881384 BP2784 U 48 C 15 (4) 18 (5) 5 (1) 18 (5) Amino acid metabolism
Hypothetical protein BP0162 NP_879055 BP0162 HP 37 U 14 (3) 9 (2) 23 (4) 23 (4) HP
Hypothetical protein BP0205 NP_879093 BP0205 HP 21 U 44 (7) 47 (8) 39 (6) 44 (7) HP/transport
Hypothetical protein BP0325^ NP_879200 BP0325 HP 43 CM 3 (1) 8 (3) 3 (1) 5 (2) HP/membrane transport
Hypothetical protein BP0387 NP_879258 BP0387 HP 27 P 27 (4) 21 (3) 32 (5) 30 (4) HP
Hypothetical protein BP0606 NP_879449 BP0606 HP 15 U 23 (2) 31 (3) 31 (3) 23 (2) HP
Hypothetical protein BP1057 NP_879842 BP1057 HP 12 U 51 (3) 23 (2) 23 (2) 39 (2) HP
Hypothetical protein BP1426 NP_880168 BP1426 HP 49 CM 20 (5) 11 (3) 7 (2) 11 (3) HP
Hypothetical protein BP1438 NP_880180 BP1438 HP 16 U 16 (2) 16 (2) 15 (2) 16 (2) HP
Hypothetical protein BP1440 NP_880182 BP1440 HP 34 U 42 (8) 36 (7) 44 (8) 42 (9) HP/protein stability
Hypothetical protein BP1485 NP_880222 BP1485 HP 58 C 42 (12) 25 (8) 31 (9) 31 (D) HP/protein transport
Hypothetical protein BP1903 NP_880589 BP1903 HP 58 CM 5 (2) 7 (2) 7 (3) 7 (2) HP
Hypothetical protein BP2141^ NP_880795 BP2141 HP 17 U 9 (1) 24 (2) 24 (2) 31 (3) HP
Hypothetical protein BP2191 NP_880839 BP2191 hﬂK 48 U 35 (8) 22 (5) 32 (8) 35 (9) HP
Hypothetical protein BP2197 NP_880845 BP2197 HP 23 U 25 (3) 47 (6) 32 (4) 35 (4) HP
Hypothetical protein BP2323 NP_880961 BP2323 HP 28 U 24 (3) 18 (2) 18 (2) 18 (2) HP
Hypothetical protein BP2534 NP_881161 BP2534 HP 58 U 25 (8) 18 (6) 18 (6) 17 (7) HP/metabolism
Hypothetical protein BP2535 NP_881162 BP2535 HP 43 CM 34 (8) 34 (8) 14 (4) 29 (7) HP/metabolism
Hypothetical protein BP2661^ NP_881275 BP2661 HP 32 U 10 (2) 5 (1) 10 (2) 10 (2) HP/transport
Hypothetical protein BP2717 NP_881325 BP2717 HP 40 M/U 29 (5) 14 (3) 5 (2) 28 (5) HP






Location T C D F Function
Hypothetical protein BP2936 NP_881518 BP2936 HP 37 U 23 (6) 17 (4) 36 (9) 33 (8) HP
Hypothetical protein BP3467 NP_881990 BP3467 HP 92 U 15 (7) 15 (7) 10 (5) 14 (7) HP/membrane biogenesis
Hypothetical protein BP3521 NP_882036 BP3651 HP 61 C 7 (3) 6 (2) 5 (2) 7 (3) HP/membrane biogenesis
Hypothetical protein BP3559 NP_882072 BP3559 HP 39 M/U 30 (6) 32 (6) 29 (6) 20 (4) HP/cell division
Hypothetical protein BP3651 NP_882159 BP3651 HP 77 U 7 (3) 7 (3) 9 (4) 8 (3) HP/membrane biogenesis
Hypothetical protein BP3689 (LysM domain/BON
SFP)
NP_882194 BP3689 HP 20 U 24 (3) 22 (3) 22 (3) 22 (3) HP/cell wall degradation
Hypothetical protein BP3758^ NP_882261 BP3758 HP 29 CM 3 (1) 5 (1) 7 (2) 7 (2) HP/membrane transport
Hypothetical protein BP3819 NP_882317 BP3819 HP 27 U 12 (2) 23 (3) 19 (2) 19 (2) HP
L-lactate dehydrogenase NP_879338 BP0484 ildD 43 C 16 (4) 19 (3) 8 (2) 28 (6) Carbohydrate metabolism
Large-conductance mechanosensitive channel NP_879158 BP0278 mscl 17 U 25 (3) 25 (3) 13 (2) 25 (3) Transport
Lipoprotein^ NP_881354 BP2750 HP 24 U 13 (2) 13 (2) 11 (2) 7 (1) U
Lipoprotein NP_879963 BP1189 U 16 U 24 (2) 39 (3) 39 (3) 25 (2) U
Mce related protein NP_882262 BP3759 U 18 U 59 (4) 35 (2) 73 (5) 45 (3) Transport
Outer membrane lipoprotein NP_881135 BP2508 omlA 20 OM 34 (3) 29 (3) 40 (4) 47 (5) Transport
Outer membrane porin protein OmpQ NP_881933 BP3405 ompQ 40 OM 30 (8) 27 (7) 23 (6) 29 (8) Transport
Outer membrane porin protein precursor NP_879650 BP0840 U 42 OM 52 (12) 43 (10) 47 (10) 43 (10) Transport
Outer membrane protein A precursor NP_879744 BP0943 ompA 21 OM 44 (7) 39 (5) 39 (6) 44 (6) Transport
Outer membrane usher protein precursor NP_880573 BP1882 ﬁmC 96 OM 10 (6) 11 (6) 13 (9) 11 (7) Membrane biogenesis
Penicillin-binding protein 1A NP_882163 BP3655 U 90 E 9 (3) 11 (4) 10 (4) 11 (5) Peptidoglycan metabolism
Putative peptidoglycan-associated lipoprotein NP_881875 BP3342 U 18 OM 59 (7) 59 (6) 67 (8) 53 (7) Transport
Peptidyl-prolyl cis-trans isomerase D NP_880447 BP1732 ppiD 7 U 45 (16) 38 (13) 38 (14) 36 (12) Protein folding
Pertactin BAF35031 U prn 101 OM 21 (13) 17 (11) 14 (8) 15 (9) Transport
Phosphoenolpyruvate synthase NP_880178 BP1436 ppsA 87 C 9 (6) 3 (2) 5 (3) 3 (2) Carbohydrate metabolism
Phosphoglucomutase/phosphomannomutase NP_879859 BP1075 qlmM 50 C 9 (3) 6 (2) 6 (2) 6 (2) Carbohydrate metabolism
Preprotein translocase subunit SecA NP_881589 BP3014 secA 100 CM 10 (7) 6 (4) 2 (2) 2 (2) Membrane transport
Preprotein translocase subunit SecD NP_879831 BP1046 secD 69 CM 28 (11) 23 (10) 29 (11) 26 (10) Membrane transport
Preprotein translocase subunit SecF NP_879830 BP1045 secF 34 CM 19 (3) 19 (3) 19 (3) 19 (3) Membrane transport
Preprotein translocase subunit SecG NP_879617 BP0802 secG 16 U 41 (2) 41 (2) 41 (2) 41 (2) Membrane transport
Putative ABC transporter NP_880959 BP2321 Pu 69 CM 16 (5) 10 (3) 15 (4) 15 (4) Transport
Putative ABC transporter ATP-binding subunit^ NP_881029 BP2397 Pu 70 CM 7 (2) 8 (2) 2 (1) 5 (1) Membrane transport
Putative ABC transporter ATP-binding subunit^ NP_880660 BP1986 Pu 70 CM 3 (1) 11 (4) 7 (2) 7 (2) Membrane transport
Putative ABC transporter ATP-binding subunit NP_882260 BP3757 Pu 31 CM 19 (3) 29 (4) 29 (4) 23 (4) Membrane transport
Putative ABC transporter ATP-binding subunit NP_880723 BP2057 Pu 46 CM 34 (7) 28 (6) 6 (2) 24 (5) Membrane transport
Putative amino acid ABC transporter ATP-binding
protein
NP_882326 BP3828 Pu 27 CM 20 (3) 15 (2) 20 (3) 15 (2) Membrane transport
Putative amino acid ABC transporter permease
protein
NP_882328 BP3830 Pu 44 CM 13 (3) 8 (2) 8 (2) 8 (2) Membrane transport
Putative bifunctional protein NP_882247 BP3744 Pu 43 CM 22 (6) 17 (4) 12 (3) 17 (4) Energy metabolism
Putative binding-protein-dependent transport
permease
NP_881026 BP2394 Pu 33 CM 5 (1) 3 (1) 7 (2) 5 (1) Membrane transport
Putative binding-protein-dependent transport
protein
NP_881859 BP3322 Pu 42 P 41 (7) 27 (6) 33 (6) 26 (4) Membrane transport
Putative cell division protein^ NP_881100 BP2473 Pu 87 CM 5 (2) 2 (1) 4 (1) 4 (3) Cell division
Putative chromosome partition protein NP_882071 BP3558 Pu 130 C 7 (6) 11 (7) 9 (6) 8 (6) Cell division
Putative dioxygenase NP_880971 BP2333 Pu 34 CM 16 (3) 19 (4) 11 (2) 19 (4) Amino acid metabolism
Putative efﬂux system inner membrane protein NP_880738 BP2075 Pu 49 CM 14 (4) 18 (5) 14 (4) 14 (4) Membrane transport
Putative efﬂux system transmembrane protein NP_880739 BP2076 Pu 118 CM 12 (9) 5 (4) 8 (7) 10 (7) Membrane transport
Putative exported solute binding protein NP_881542 BP2963 Pu 40 U 17 (4) 10 (2) 10 (2) 13 (3) Membrane transport
Putative extracellular solute-binding protein NP_880657 BP1983 Pu 82 P 6 (3) 6 (3) 6 (3) 6 (3) Membrane transport
Putative glycosyl transferase NP_881785 BP3238 Pu 34 U 20 (4) 10 (2) 12 (2) 22 (4) Metabolism
Putative inner membrane protein NP_881862 BP3326 Pu 26 U 27 (4) 27 (4) 28 (4) 49 (6) HP
Putative inner membrane protein translocase
component YidC
NP_886531 BBP4405 Pu 62 CM 9 (3) 15 (4) 12 (4) 7 (3) Membrane transport
Putative inner membrane-anchored protein NP_880838 BP2190 Pu 33 U 16 (4) 20 (5) 20 (4) 15 (3) HP
Putative integral membrane protein NP_881049 BP2420 Pu 41 CM 9 (2) 12 (2) 16 (4) 7 (2) Membrane transport
Putative L-lactate dehydrogenase NP_879251 BP0379 Pu 39 C 7 (2) 18 (3) 18 (3) 21 (4) Carbohydrate metabolism
Putative lipoprotein NP_880735 BP2072 Pu 22 U 24 (3) 27 (3) 24 (3) 18 (2) Putative transport
Putative lipoprotein NP_881568 BP2992 Pu 18 OM 59 (6) 49 (5) 53 (5) 53 (5) Putative transport
Putative lipoprotein NP_882263 BP3760 Pu 29 OM 13 (2) 25 (4) 16 (4) 11 (3) Putative transport
Putative lipoprotein NP_880063 BP1296 Pu 30 U 16 (3) 12 (2) 12 (2) 12 (2) U
Putative lipoprotein NP_880303 BP1296 Pu 41 U 26 (5) 30 (6) 22 (5) 30 (7) Putative membrane
biogenesis
Putative lipoprotein NP_880710 BP2043 Pu 24 U 26 (4) 15 (2) 23 (4) 11 (2) U
Putative membrane transport ATPase NP_881330 BP2722 Pu 86 CM 4 (2) 4 (2) 3 (2) 5 (2) Putative transport
Putative membrane transport protein NP_881309 BP2716 Pu 49 U 7 (2) 7 (2) 11 (3) 7 (2) Putative transport
Putative NADH dehydrogenase NP_882010 BP3491 ndh 48 CM 10 (3) 6 (2) 6 (2) 6 (2) Energy metabolism
Putative outer membrane (permeability) protein NP_881865 BP3329 Pu 87 OM 16 (7) 9 (4) 12 (6) 10 (5) Putative transport
Putative outer membrane ligand binding protein NP_879893 BP1112 bipA 144 OM 39 (28) 15 (12) 23 (17) 13 (12) Adherence
Putative peptidase NP_880436 BP1721 Pu 32 OM 22 (3) 20 (3) 20 (3) 27 (4) Protein degradation
Putative quinoprotein NP_880844 BP2196 Pu 42 OM 31 (6) 29 (5) 38 (7) 20 (4) Protein assembly
Putative secreted protein^ NP_879832 BP1047 Pu 13 U 32 (2) 32 (2) 32 (2) 21 (1) Membrane transport
Putative secretion system protein NP_882292 BP3793 ptle 26 U 14 (3) 21 (4) 17 (3) 16 (3) Putative transport
Putative secretion system protein NP_882293 BP3794 ptlf 30 U 11 (2) 19 (3) 19 (3) 11 (2) Putative transport
Putative secretion system protein NP_882289 BP3794 ptlc 91 CM 6 (3) 9 (5) 9 (5) 11 (6) Putative transport
(continued on next page)
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Putative sugar transport protein^ NP_881176 BP2549 Pu 61 CM 5 (2) 2 (1) 5 (2) 5 (2) Putative transport
Putative sulfatase NP_881701 BP3136 Pu 72 CM 21 (8) 10 (5) 17 (8) 17 (8) Membrane biogenesis
Putative TolQ-like translocation protein NP_881879 BP3346 Pu 25 CM 22 (3) 22 (3) 23 (4) 19 (3) Membrane transport
Putative type III secretion protein NP_880879 BP2235 Pu 66 CM 8 (3) 10 (3) 12 (5) 12 (4) Membrane transport
Pyrroline-5-carboxylate reductase NP_880048 BP1280 proC 30 C 15 (3) 15 (3) 10 (2) 11 (2) amino acid metabolism
RecA AAK85426 U recA 31 C 36 (6) 31 (5) 28 (4) 22 (4) DNA processing
Ribonuclease E NP_879331 BP0475 rne 115 C 12 (8) 8 (5) 6 (4) 8 (5) RNA degradation
Ribonucleotide-diphosphate reductase subunit alpha NP_881559 BP2983 nrdA 107 C 10 (7) 5 (3) 3 (2) 8 (5) Nucleotide metabolism
RNA polymerase sigma 80 subunit AAC45085 BP1191 rpoD 81 C 9 (4) 5 (2) 6 (3) 6 (2) RNA processing
Rod shape-determining protein NP_879246 BP0374 mreB 38 C 16 (3) 19 (4) 8 (2) 12 (3) Cell morphology
SCO1/SenC family protein^ NP_882237 BP3734 U 22 U 17 (3) 6 (1) 10 (2) 6 (1) Transport
Serum resistance protein NP_882013 BP3494 brkA 111 OM 23 (14) 27 (14) 29 (17) 38 (21) Transport
Signal peptidase I NP_881060 BP2432 lep 32 CM 11 (2) 19 (4) 14 (3) 12 (2) Transport
Succinate dehydrogenase ﬂavoprotein subunit^ NP_880997 BP2361 sdhA 65 CM 7 (3) 7 (3) 3 (1) 11 (5) Carbohydrate metabolism
Succinate dehydrogenase iron–sulfur protein^ YP_785707 BAV1185 sdhB 26 CM 4 (1) 14 (4) 9 (3) 14 (3) Carbohydrate metabolism
Succinyl-CoA synthetase subunit beta NP_881168 BP2541 sucC 42 U 14 (3) 9 (2) 9 (2) 17 (4) Carbohydrate metabolism
Surface antigen NP_880169 BP1427 U 86 OM 29 (15) 29 (15) 25 (13) 35 (18) Protein assembly
Tex CAA64672 BP1144 tex 87 C 5 (3) 4 (2) 3 (2) 4 (2) RNA processing
Thiol:disulﬁde interchange protein NP_882154 BP3646 DsbA 71 CM 15 (7) 14 (6) 14 (6) 10 (4) Membrane biogenesis
Threonine synthase NP_881383 BP2783 thrC 51 C 16 (5) 31 (9) 10 (3) 17 (5) Amino acid metabolism
TonB-dependent receptor for iron transport NP_879666 BP0856 bfrD 82 OM 34 (20) 35 (21) 29 (18) 28 (15) Membrane transport
Tracheal colonization factor precursor NP_879974 BP1201 tcfA 71 OM 12 (6) 20 (8) 19 (10) 10 (6) Membrane transport
Translocation protein TolB NP_881876 BP3343 tolB 48 P 13 (3) 15 (4) 21 (6) 14 (4) Transport
Trifunctional transcriptional regulator/proline
DH/P-5-C DH
NP_881353 BP2749 putA 140 C 11 (9) 10 (8) 14 (12) 14 (12) Amino acid metabolism
Twin argininte translocase protein A NP_882278 BP3777 tatA 8 U 35 (2) 35 (2) 35 (2) 35 (2) Membrane transport
Type II citrate synthase NP_880994 BP2358 qltA 48 C 11 (3) 8 (2) 10 (3) 10 (3) Carbohydrate metabolism
Ubiquinol oxidase polypeptide I NP_881514 BP2932 cyoB 72 CM 6 (3) 6 (2) 9 (4) 6 (2) Energy metabolism
Uridylate kinase NP_880163 BP1421 pyrH 26 C 13 (3) 10 (2) 23 (4) 16 (3) Nucleotide metabolism
Virulence factors transcription regulator NP_880570 BP1878 bvgA 23 C 43 (7) 59 (9) 52 (8) 34 (5) Signal transduction
DNA polymerase I NP_880026 BP1254 polA 99 C 5 (3) 5 (3) Nucleotide metabolism
Acetyl-CoA synthetase NP_881040 BP2409 acsA 72 C 6 (3) 4 (2) Carbohydrate metabolism
2-Oxoglutarate dehydrogenase E1 component^ NP_879903 BP1124 sucA 106 C 2 (1) 4 (2) Metabolism
Probable Orn/Arg/Lys decarboxylase^ NP_879079 BP0190 U 83 C 3 (1) 4 (2) Amino acid metabolism
Autotransporter NP_879378 BP0529 U 246 OM/E 7 (2) 5 (6) 2 (2) Membrane transport
Cytochrome B^ NP_879156 BP0276 petB 51 CM 17 (5) 3 (1) 5 (2) Energy metabolism
DNA mismatch repair protein^ NP_879129 BP0244 mutL 69 C 4 (2) 6 (2) 5 (1) DNA processing
HP BP3084 NP_881655 BP3084 HP 41 C 18 (4) 17 (4) 10 (2) HP
Ubiquinol-cytochrome C reductase iron–sulfur
subunit
NP_879157 BP0277 petA 23 CM 24 (3) 24 (3) 19 (2) Energy metabolism
30s ribosomal protein S20^ NP_881377 BP2773 rspT 90 U 14 (2) 13 (1) 14 (2) Translation
Putative membrane-bound transglycosylase^ NP_881812 BP3268 Pu 47 OM 4 (1) 14 (4) 16 (4) Membrane biogenesis
Putative transglycosylase^ NP_881631 BP3060 Pu 76 P 4 (2) 4 (1) 4 (1) Membrane biogenesis
Dermonecrotic toxin NP_881965 BP3439 dnt 161 U 5 (4) 2 (2) 4 (4) Cell death
Putative periplasmic solute-binding NP_880224 BP1487 smoM 40 U 8 (2) 8 (2) 16 (4) Putative transport
Serotype 3 ﬁmbrial subunit NP_880302 BP1568 ﬁm3 22 E 20 (3) 27 (4) 15 (2) Cell integrity
CTP synthetase (synthase) NP_881022 BP2389 pyrG 61 C 5 (2) Nucleotide metabolism
Cycolysin secretion protein NP_879580 BP0762 cyaD 48 CM 12 (3) Membrane transport
HP BP1123 NP_879902 BP1123 HP 75 U 11 (5) HP
Putative ketopantoate reductase NP_880110 BP1360 Pu 34 C 10 (2) HP/metabolism
Putative transcriptional regulation protein NP_881198 BP2571 Pu 15 U 27 (2) HP/RNA processing
Serotype 2 ﬁmbrial subunit P05788 BP1119 ﬁm2 23 E 21 (2) Cell integrity
Threonyl-tRNA-synthetase NP_880233 BP1497 thrS 71 C 8 (3) Translation
ABC transport protein, ATP-binding component NP_881414 BP2816 metN 40 CM 10 (2) Membrane transport
HP BP3441 NP_881967 BP3441 HP 36 M/U 19 (3) HP
BpH2 (novel histone — 18323) AAB40156 U bph2 16 U 19 (2) DNA processing
Putative heme receptor NP_879314 BP0456 hemC 82 OM 6 (3) Membrane transport
Trigger factor NP_880485 BP1774 tig 48 U 8 (2) Cell division
Exopolyphosphatase NP_879857 BP1073 ppx 55 C 4 (2) Nucleotide metabolism
HP BP2486 NP_881113 BP2486 HP 45 CM 8 (2) HP
HP BP3002 NP_881577 BP3002 HP 69 C 6 (2) HP
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and comprised 27% of the total surfaceome (Table 2B).
In general, the identiﬁed proteins included, but were not limited
to, secreted proteins and toxins, as well as outer membrane proteins
afﬁliated with cell membrane synthesis, cellular transport, adhesion,
pathogenesis, or virulence. Additionally, the EMF proteomic proﬁles
consisted of proteins associated with protein synthesis. These includ-
ed highly abundant ribosomal proteins and elongation factors, DNA
synthesis-associated proteins, metabolic enzymes, and hypothetical
proteins (HP) with unknown functions (Table 2C).In all, we discovered 163 proteins in the EMFs of all four strains
(Table 2D). Among themwere the expected surface proteinsﬁlamentous
hemagglutinin adhesin (FHA) and pertactin (Prn), OmpQ, a serum resis-
tance protein (BrkA), a TonB-dependent receptor for iron transport
(TonB), a tracheal colonization factor precursor (TcfA), 30S ribosomal
proteins S2 and S3, chaperonin GroEL (GroEL), and elongation factor Tu
(EF-Tu). Common proteins were also identiﬁed in a combination of
two or three strains and absent in the remaining. Other proteins were
detected only in T while absent in C, D, and F, including CTP synthetase,
HP Bp 1123 and, a putative ketopantoate reductase among others.
Table 3A
Summary of identiﬁed Bp putative immunogenic proteins using the mouse model
(** — Table 2A). Abbreviations: T — Tohama I, C — C056, D — D946 and F — F656;
CR — cross-reactivity, NS — non-speciﬁcity, IgG — immunoglobulin G, EMF —
enriched membrane fraction, PIPs — putative immunogenic proteins.
T C D F
Total PIPs 19 31 31 12
Total PIPs with CR or NS with normal mouse IgG bound-
beads
6 7 12 4
Total PIPS without CR or NS with normal IgG bound-beads 13 24 19 8
% of total surfaceome (EMF) with tentative antigenic protein
potential
11% 18% 18% 7%
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present in T, such as a putative periplasmic solute-binding protein. Lastly,
proteins were identiﬁed exclusively to C, D, or F. These included HP
Bp 3441, a trigger factor, and an exopolyphosphatase, respectively
(Table 2D).
3.3. Direct putative immunoreactive protein identiﬁcation using nLC
ESI-MS/MS
To identify putative antigenic proteins directly from the EMFs and
to ascertain any differential immunoreactive proteomic proﬁles
among the four strains, antigen-antibody (Ag-Ab) afﬁnity capture
technologies were employed. Trypsin-digested EMF proteins immu-
noprecipitated with coupled magnetic-bead strain-speciﬁc mouse
antisera were analyzed via nLC-ESI MS/MS. Among each of the strains
T, C, D, and F, 19, 31, 31, and 12 total “putative immunogenic pro-
teins” (PIPs) were identiﬁed by database search analysis, respectively
(Table 3A). Of the 48 total distinct PIPs detected between all 4 strains,
50% were membrane-associated with 60% of these proteins localized
to the outer membrane and/or extracellular. The remaining 24 PIPs,
accounting 23% and 27% were localized to the cytoplasm or of un-
known location, respectively. For example, Prn, TonB, GroEL, EF-Tu,
and a putative sulfatase were some of the proteins identiﬁed among
all the strains (Table 3B). Collectively, the common PIPs (bold-black
outlined box) detected in all T, C, D, and F strains were OmpQ,
OmpP, putative lipoprotein, OmpA, BrkA, TcfA, and HP Bp 1440. Alter-
natively, a Vag8 autotransporter, preprotein translocase SecD (SecD),
a putative peptidoglycan-associated protein, SCO1/SencC family and a
thiol:disulﬁde interchange protein (DsbA) were identiﬁed in only C,
D, and F (blue shaded box) and not detected in the T-EMF/Ab immu-
noprecipitated complex. Five, 11, and 9 strain-speciﬁc PIPs were
detected in the T-, C- and D-EMF Ab-bead complexes. Included
among those were HP Bp 0455, a putative inner membrane protein,
and a putative bifunctional protein, respectively (Table 3B). No
strain-speciﬁc PIPs were detected in the F-EMF/Ab IP complex. It is
worth noting that varying degrees of cross-reactivity (CR) or nonspe-
ciﬁc (NS) interactions were generated (denoted with an asterisk)
using stable IP between the strains' EMF to the normal mouse IgG-
bound bead control. And these interactions can be reasonably
explained from a biological perspective as depicted in Fig. 3. TcfA,
OmpP, and OmpA with evident cross reactivity were discovered in
all 4 strains. Furthermore, the total PIPs correlating to mouse pertus-
sis immunity comprised 11, 18, 18, and 7% of total T, C, D, and F sur-
faceome proteomic proﬁles, respectively (Table 3A). But taking any
tentative cross-reactivity into consideration, subtracting the nonspe-
ciﬁc interactions from the total number of PIPs resulted in a 23–39%
reduction of more probable antigenic candidates.
Finally, we performed a MS-based immunoproteomic study using
coupled magnetic bead-pooled human convalescent serum in combi-
nation with EMFs. This was to identify novel antigenic proteins that
potentially correlate with human response to pertussis infection.
The study, as summated in Tables 4A and 4B, revealed that human an-
tibodies contained in the pooled serum immunoreacted with 4, 12, 8,
and 10 proteins present in T-, C-, D-, and F-EMFs, respectively.Moreover, of the 15 total distinct PIPs detected by nLC-ESI MS/MS
among all 4 strains, more than half were extracellular or localized to
the outer membrane, including Vag8, BrkA, and TonB. Five proteins:
HP Bp 0205, HP Bp 1485, HP Bp 3689, a probable inner membrane,
and TonB revealed strain-speciﬁc detection in the human IP. Only
two – a probable inner membrane protein and HP Bp 3689 – were
unique to C and F, respectively. Once again, accounting for any non-
speciﬁc interactions between normal human IgG antibodies and the
EMFs, the pool of PIPs identiﬁed in this foundational assessment is di-
minished to 1, 3, 0, and 5 for T, C, D, and F, respectively. Lastly, in both
the mouse and human immunoproteome examinations, 14 proteins
were commonly identiﬁed, of which OmpQ and OmpA were the
only proteins detected in all four immune complexes.
4. Discussion
In spite of widespread vaccination, disease caused by Bp is rapidly
increasing in the United States. In this pilot study we compared
the proteomes of one past Bp strain with three current circulating
strains in which any subtle changes in their proteome proﬁle could
have pathogenic and immunological implications. Additionally, we
employed a non gel-based technique to compare surface proteins
and immunoproteins from the four Bp strains. Previous studies of bac-
terial surfaceomes for the identiﬁcation of clinical diagnostic
biomarkers (and more so, novel vaccine candidates) have all incorpo-
rated approaches that involve to a certain extent subproteome frac-
tionation and gel-based separation followed by MS and protein
identiﬁcation (Thein et al., 2010). Our initial path of study in charac-
terizing the surfaceomes of three recent Bp circulating isolates and
one older isolate from 1954 began with a 1D-GE EMF protein assess-
ment. This revealed no major protein banding differences or unique
patterns. In an effort to maximize protein discovery, however, we
implemented a gel-free surfaceome proﬁling approach. This proved
advantageous and fruitful in identifying total proteins and was in par-
tial concurrence with previous Bp surfaceome analysis.
Bottero et al. (2007) described a comparative surfaceome analysis
of 3 Bp vaccine producing strains. The methodology included T and an
Argentinean clinical isolate 106, in which 54 total proteins from
enriched Bp surface extracts were identiﬁed using 2D-GE in parallel
with matrix-assisted laser desorption ionization-time-of-ﬂight
(MALDI-TOF) MS analysis.
In our direct nLC-ESI MS/MS Bp surface assessment, 139 more pro-
teins were identiﬁed than in the gel-based Bottero study (Bottero
et al., 2007). Bottero similarly identiﬁed 21 of the total 193 proteins,
of which approximately 40% of this subset localized to the outer
membrane. These included a competence lipoprotein, FHA, OmpQ,
OmpP, OmpA, Prn, BrkA, and a putative quino protein. Among the cy-
toplasmic proteins, both studies discovered a capsular polysaccharide
biosynthesis protein, putative L-lactate dehydrogenase, GroEL, and
EF-Tu. And as summated in Table 2D, the remaining 172 proteins
identiﬁed in our study were localized to the membrane or cytoplasm.
They either “moonlight” (perform multiple cellular roles), serve in a
cellular housekeeping capacity such as energy production, or engage
in membrane-associated activities such as biogenesis, adhesion, or
transport.
Our surfaceome proﬁle resulted in a higher number of proteins
identiﬁed. Given that our preparation is enriched and not exclusive
for the surface membrane, more nonsorted cytoplasmic proteins
may have been retained in the fraction compared with Bottero's en-
richment method, thus resulting in more proteins in the starting ma-
terial. Additionally, the proﬁle generated is a direct analysis of a
conformationally native in-solution protein pool versus a protein-
embedded, gel excised spot or band. Consequently, this state would
ideally allow proteolytic enzymes greater accessibility to the protein
itself and result in a potentially higher yield of peptides generated
by tryptic digestion. MALDI-TOF is a fruitful MS technology, in
Table 3B
Putative Bp immunogenic proteins identiﬁed among Bp strains assessed in the study. Values noted represent percent amino acid coverage of the identiﬁed IP protein using the mouse
model. (Number of uniquepeptides detected in parenthesis.). No numerical value noted indicates that theproteinwas not identiﬁed in themouse IP. (^) indicates that identiﬁedproteins
only had one unique detected tryptic peptide. Asterisk (*) indicates that the protein identiﬁed in themouse IPwas cross-reactivewith normalmouse IgG-boundbeads. Blue-shaded box:
common in all 3 clinical isolates; black-bordered box: common in all 4 strains. Abbreviations: T— Tohama I, C— C056, D—D946 and F— F656; OM— outermembrane, CM— cytoplasmic













Elongation factor Ts 
CAE33099
34      
Elongation factor Tu 
NP_878925
44      
F0F1 ATP synthase subunit B^ 
NP_881826
17      
Fructose-1,6-bisphosphate aldolase 
NP_880254
39      
Glyceraldehyde-3-phosphate dehydrogenase 
NP_879794
37      
HP BB 4955 
NP_891489
74      
HP BP 0205 
NP_879093
21      
HP BP 0455 
NP_879313
74      
HP BP 1057 
NP_879842
12      
HP BP 1440^ 
NP_880182
34     
HP BP 1485^ 
NP_880222
58      
HP BP 2191 
NP_880839
48      
ketol-acid reductoisomerase 
NP_879606
37      
N-acetyl-gamma-glutamyl-phosphate reductase 
NP_881539
39      
Outer membrane porin protein OmpQ 
NP_881933
40      
Outer membrane porin protein precursor 
NP_879650
42      
Outer membrane protein A precursor 
NP_879744
21      
Pertactin^ BAF35031 101      
Phospho-2-dehydro-3-deoxyheptonate aldolase 
NP_881490
39      
Preprotein translocase subunit SecD 
NP_879831
69   5(2) 7(3)* 5(2) 
Putative bifunctional protein 
NP_882247
43      
Putative binding-protein-dependent^ 
NP_881859
42      
Putative efflux system transmembrane…^ 
NP_880739
118      
Putative exported solute binding protein 
NP_881542
40      
Putative inner membrane protein 
NP_881862
26      
Putative inner membrane protein 
NP_886531
62      
Putative inner membrane-anchored protein 
NP_880838
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Putative periplasmic solute-binding protein NP_880224 40      
Putative secreted protein^ NP_879832 13      
Putative sulfatase NP_881701 72      
Probable inner-membrane protein CAE35357 61      












SCO1/SenC family protein^ NP_882237 22   6(1) 6(1) 6(1) 
Serotype 3 fimbrial subunit  NP_880302 22      
Serum resistance protein (BrkA) NP_882013 111      
Signal peptidase I NP_881060 32      
Surface antigen NP_880169 86      
Thiol:disulfide interchange protein NP_882154 71   3(2) 3(2)* 3(2) 
TonB-dependent receptor for iron transport  NP_879666 82      



















Putative L-lactate dehydrogenase NP_879251 39      
Putative lipoprotein NP_881568 18      
Putative lipoprotein NP_880303 41      
Putative outer membrane ligand binding protein NP_879893 144      
Putative peptidase NP_880436 32      
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of accuracy, peptide capacity, peptide resolution, and detection sensi-
tivity, the nLC-ESI MS/MS used in our study is more advantageous and
lends itself to higher numbers of proteins identiﬁed.
Other factors such as database annotation, peptide ionization po-
tential, subproteome extraction, and protein abundance can also af-
fect the success of protein identiﬁcation. First, the Bp clinical isolates
used in these studies have yet to be sequenced and thus are not pre-
sent in the database. Therefore, some MS/MS data may not be
matched to proteins in the existing database, resulting in lower pro-
tein discovery. Also, as in the case for both studies, due to amino
acid composition (i.e., hydrophobic peptides) some peptides do not
ionize well. Thus, their abundance may not be enough to trigger the
mass spectrometer to conduct an MS/MS experiment. And some pep-
tides may not fragment efﬁciently, leading to complete inability for
the searching algorithm to match the data to the protein, irrespective
of the MS instrumentation used. Again, due to chemical composition
of the proteins and the extraction buffers utilized, some proteins
may even be lost in the preparation (Bottero et al., 2007; Altindis
et al., 2009). Note too that proteins commonly identiﬁed between
both studies are cellularly abundant (i.e. EF-Tu) and large in molecular
weight (i.e., FHA). Consequently, when these proteins are enzymatically
digested they will likely generate more peptides that would have a
greater propensity of detection. This could hinder the detection of
smaller proteins, which obviously would have fewer tryptic peptides.Though our direct, gel-free, EMF nLC-ESI MS/MS analysis may require
optimization of extraction steps to ensure a greater retention of outer
membrane proteins and reduce “contamination” by abundant cytoplas-
mic proteins thatmay overshadow less abundant proteins, the approach
can be used to examine other Bp circulating isolate surfaceomes for
novel surface-expressed protein discovery.
The next phase of our study moved from elucidating what pro-
teins comprised the enriched surfaceome to what proteins actually
have the ability to induce an Ab-mediated response. We deviated
from classical immunoblotting techniques, such as those used by
Altindis et al. (2009), for a less-labor intensive, more rapid Ag–Ab af-
ﬁnity approach. The Ag–Ab method has an added beneﬁt of identify-
ing surface proteins with both continuous and noncontinuous
epitopes while immunoblotting techniques generally can only probe
continuous epitopes. Today, conjugated Ab-magnetic bead capture
technologies are widely used for protein IP. Generally, protein G-
coated magnetic Dynal™ beads capture from antisera IgG populations
traditionally associated with direct Ab-mediated immune responses.
This Ab-bead complex is immunoprecipitated or “pulled down”
with proteins, if immunostimulatory would uniquely “match” and in-
teract with its speciﬁc Ab. Once the protein-Ab-bead complex is
pulled-down and washed to remove nonspeciﬁc binding, the beads
are subjected to enzymatic digestion by trypsin and the peptides are
analyzed by nLC-MS/MS. The respective proteins are identiﬁed by da-
tabase searching.
Fig. 3. Illustration of potential speciﬁc and non-speciﬁc interactions during an immunoprecipitation (IP) from a biological and technical perspective.
130 Y.M. Williamson et al. / Journal of Microbiological Methods 90 (2012) 119–133Kudva et al. (2005) used this Ab-bead capture technology to iden-
tify anthrax spore surface proteins in response to human anthrax vac-
cine adsorbed-induced immunity. Here we similarly describe the use
of Ag–Ab afﬁnity for stable IP of Bp EMFs using strain-speciﬁc mouse-
antisera, and couple this technique to MS to identify novel putative
antigenic proteins. Of the 48 total proteins detected among our
strains, 10 well-known immunogens were identiﬁed, including
Vag8, GroEL, Prn, BipA, serotype 3 ﬁmbrial subunit (Fim3), BrkA,
OmpQ, OmpP, OmpA and TcfA (van den Berg et al., 1999; Oliver and
Fernandez, 2001; Fuchslocher et al., 2003; Elder and Harvill, 2004;
Matoo and Cherry, 2005; Zhu et al., 2010). The latter ﬁve are com-
monly detected in all four strains. Other known Bp immunogens
such as Ptx, FHA, Dnt, Fim2, or CyaA, the latter four identiﬁed in our
total surfaceome proﬁle, may have been immunoprecipitated and,
due to peptide composition, simply not detected by MS. EF-Tu, EF-
Ts, glyceraldehyde-3-phosphate dehydrogenase (Gdh), and a puta-
tive L-lactate dehydrogenase (Ldh) are immunogens commonly con-
served in other pathogens (Zhu et al., 2010; Chitlaru et al., 2007;
Ling et al., 2004) were also identiﬁed in our Bp afﬁnity capture assess-
ment. Additionally, Altindis et al. (2009) used strain-speciﬁc mouse
antisera to perform a 2D-GE immunoproteomic study aimed at iden-
tifying novel immunogens in T and in the Bp Saadet strain, a 1948
Turkish isolate. The Altindis study discovered 25 total proteins, of
which EF-Tu, Prn, BrkA, and ketol-acid reductoisomerase were com-
parably identiﬁed in all or some of the isolates in our examination.Table 4A
Summary of identiﬁed Bp putative immunogenic proteins using the human model
(** — Table 2A). Abbreviations: T — Tohama I, C — C056, D — D946 and F — F656;
CR — cross-reactivity; NS — non-speciﬁcity; IgG — immunoglobulin G; EMF —
enriched membrane fraction; PIPs — putative immunogenic protein.
T C D F
Total PIPs 4 12 8 10
Total PIPs with CR or NS with normal mouse IgG bound-beads 3 9 8 7
Total PIPS without CR or NS with normal IgG bound-beads 1 3 0 3
% of total surfaceome (EMF) with tentative antigenic protein
potential
1% 2% 0% 2%Even more, Tefon et al. (2011) described an extension of the 2009
Altindis study using 2D-GE in parallel with nLC-MS/MS to identify
11 more immunogens of Bp T and the Saadet strain, of which three
– Prn, GroEL and BrkA – were, as stated, discovered in our study.
Identiﬁcation of more similar proteins from the Altindis and Tefon
studies is likely dependent on differential method design. Neverthe-
less, these proteins, along with the OmpP and OmpQ comparably
identiﬁed in both our pilot immunoblot and IP study, in addition to
the other known antigen identiﬁcations are conﬁrmation that the
capture technology is a fruitful alternate approach available for Bp im-
munogen discovery.
Of the remaining PIPs determined as common among T, C, D, and
F, HP Bp 1440 and a putative lipoprotein are both possibly associated
with transport and adhesion and could be considered as novel puta-
tive Bp antigens. Moreover, of the 5 PIPs only detected in the recent
circulating C, D, and F isolates, only Vag8 was previously identiﬁed
as immunogenic. The putative peptidoglycan associated-lipoprotein,
SCO1/SenC family protein, DsbA, and SecD are proteins involved in
outer membrane lipid attachment; membrane biogenesis and cyto-
chrome c assembly, protein turnover, protein folding and energy pro-
duction; and membrane protein secretion and export, respectively
(Parkhill et al., 2003). Note too that their unique identiﬁcation to
the clinical strains could provide insight into the overall immuno-
pathogenesis of past and recent pertussis cases.
Even more, immunogen screening via IP also identiﬁed PIPs
unique to each strain. First, the T-EMF study detected ﬁve speciﬁc
PIPs, one of which is BipA, a known immunogen. HP Bp 0455 and its
Bordetella bronchioseptica (Bb) BB4955 homolog, both putatively as-
sociated with organic anion transport, also were identiﬁed (Parkhill
et al., 2003), as were a putative inner membrane protein (Bp 3326)
and a surface antigen, similar to the outer membrane protein assem-
bly complex YaeT.
Second, the C-EMF study detected 11 speciﬁc PIPs, which includ-
ed previously identiﬁed immunogens EF-Ts, GDH, LDH, and ketol-
acid reductoisomerase. Fructose 1-6-bisphosphate aldolase (Fba), N-
acetyl-gamma-glutamyl-phosphate reductase (ArgC), and phosphor-2-
dehydro-3-deoxyheptonate aldolase (AroG) are all metabolic enzymes
Table 4B
Putative Bp immunogenic proteins identiﬁed among Bp strains assessed in the study. Values noted represent percent amino acid coverage of the identiﬁed IP protein using the
human model. (Number of unique peptides detected in parenthesis.). No numerical value noted indicates that the protein was not identiﬁed in the human IP. (^) indicates that
identiﬁed proteins only had one unique detected tryptic peptide. Asterisk (*) indicates that the protein identiﬁed in the human IP was cross-reactive with normal human IgG-
bound beads. Pink-shaded box — protein identiﬁed in human and mouse IP; yellow-shaded box — strain-speciﬁc protein identiﬁcation only in human IP; black-bordered box:
common in all 4 strains. Abbreviation: T — Tohama I, C — C056, D — D946 and F — F656.
Protein Accession #  T C D F 
Autotransporter (Vag8) NP_880953 12(8)* 17(12)* 7(4)* 
HP BP 0205^ NP_879093 6(1)* 21(4)
HP BP 1440 NP_880182 10(3)  27(5)* 11(3) 
HP BP 1485 NP_880222 9(3)* 16(7)* 6(2) 
HP BP 3689 NP_882194 18(2) 
Outer membrane porin protein OmpQ^ NP_881933 3(1)* 7(2)* 11(3)* 4(1)* 
Outer membrane porin protein precursor NP_879650 23(6)* 21(7)*
Outer membrane protein A precursor NP_879744 10(3)* 21(5)* 21(5)* 17(3)* 
Preprotein translocase subunit SecD NP_879831 12(5)*  
Probable inner membrane protein CAE35357 4(2)*   
Putative lipoprotein NP_881568 37(3)*  22(2)* 
Serum resistance protein (BrkA) NP_882013 2(2)*   
Thiol:disulfide interchange protein NP_882154 3(2)
TonB-dependent receptor for iron transport  NP_879666 7(4) 19(11)* 3(2) 
Tracheal colonization factor protein NP_879974 9(4)* 10(5)* 7(3)* 
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(Parkhill et al., 2003; Matoo and Cherry, 2005). Two proteins, similar
to the bacterial, extracellular solute-binding protein family 7, exported
solute-binding and periplasmic solute-binding (SmoM) were also
found to be immunostimulatory (Parkhill et al., 2003; Matoo and
Cherry, 2005). A rod-shape determining protein associated with the
MreBCD complex was also identiﬁed.
Third, the D-EMF study detected nine speciﬁc PIPs, which included
HP BP1057—a protein similar to E. coli Elab. A putative bifunctional
protein, a metabolic protein similar to P. aeruginosa cytochrome c ox-
idase, and a F0F1 ATP synthase subunit B (an enzyme part of the
membrane proton pump involved in ATP synthesis) were discovered.
A probable Bp inner membrane protein and its homologous Bb
translocase YidC, a membrane insertase, were identiﬁed as immuno-
reactive. A putative peptidase, associated with bacterial wall degrada-
tion and a signal peptidase I – an enzyme similar to the essential
membrane bound serine protease leader peptidase B –were uniquely
immunoprecipitated in the D antibody/EMF complex. A putative sul-
fatase containing phosphoglycerol transferase activity-like domains
possibly associated with cell envelope biogenesis, was also discov-
ered. Protective antibodies, for instance generated against this sulfa-
tase, if not expressed in humans, could potentially impair bacterial
cell growth and ultimately reduce infectivity and transmission of per-
tussis. Lastly, of the 14 PIPs identiﬁed in F, none were unique to this
isolate.
Moreover, with differential and lower immunoreactivity among
the strains, as in the case with strain F, one may wonder why varia-
tion exists and the usefulness of strain-speciﬁc PIPs as potential can-
didates for clinical diagnostics and improved vaccine development.
First, an important reminder is that Bp T is a lab-adapted strain in
which virulence observed over the years may have weakened, reduc-
ing its immunopotency and contributing to fewer PIPs identiﬁed.
Second, C, D, and F strains all were isolated in different U.S. geo-
graphical regions between 1998 and 2007 and presumably from dif-
ferent individuals, thus, the identiﬁcation of unique, strain-speciﬁc
PIPs is not unlikely. Also, although Bp T, C, D, and F OMP extraction
and enrichments were performed under the same conditions and
time, some proteins exhibiting antigenic properties might have
been lost during the preparation process. Nevertheless, regardless of
strain differences, all the aforementioned PIP biological roles could
prove insightful into the overall immunopathogenesis of Bp and pro-
vide a greater epidemiological understanding of pertussis incidenceand how better to diagnose, treat, and – most importantly – prevent
the disease.
As alluded, though speciﬁc Ag–Ab interactions were formed and
measures taken in the method to reduce nonspeciﬁc binding, cross-
reactivity of strain-speciﬁc Ags from the EMFs to normal mouse IgG-
bound bead controls was observed. Proteins commonly immunopreci-
pitated in all strains, such as OmpQ and OmpA, exhibit cross-reactive
or nonspeciﬁc tendencies and are reasonably explained from a biologi-
cal perspective (Fig. 3). First, the EMF protein interactive with the Ab-
bead in its natural state exists as a complex. Second, because not all
of the available sites on the protein G-beads will be occupied by
IgG-speciﬁc antibodies, Bp proteins present in the EMF with bio-
chemical properties that allow for interaction directly to the protein
G could exist. Third, Bp proteins could nonspeciﬁcally bind to
glycoprotein-antibody moieties. Also, cross-reactivity may simply
persist due to protein abundance in which residual amounts of de-
tectable protein remain even after several washes upon IP and before
protein digestion. Under all of these scenarios, upon tryptic digestion
not only the bound speciﬁc protein is digested, but also thosemaking
up complex formations are digested as well, all of which could be
simply considered as nonspeciﬁc. With all that said, regardless of
the origin of cross-reactivity, identiﬁed immunogens are merely pu-
tative. To be considered true candidates as biomarkers for clinical
diagnostics and improved vaccine development, they have to be
validated extensively on a proteomic level and, most importantly,
in vivo.
Information gained from immunoproteomic studies that use Bp-
generated mouse antisera as the basis for novel immunogen discov-
ery are quite valuable to identify possible immunoreactive proteins.
But individual, Bp-stimulated human antibody or pooled serum from
actively infected or even convalescent pertussis patients is more
ideal and provides a more relevant immunological perspective of
human pertussis infection. In our study, 15 total PIPs among T, C,
D, and F were recognized by pooled human antibodies from patients
recovering from pertussis infection—a more than 3-fold reduction in
total PIPs identiﬁed using the mouse model. Moreover, strain-
speciﬁc antisera generated from whole inactivated Bp T, C, D, and
F from immunized animals versus a pooled serum from convales-
cent pertussis-infected human patients are a clear factor that may
play a role in differential immunoreactivity. Although not compara-
ble with methodologies performed in our study, Zhu et al. (2010)
recently described a 2D-GE proteomic assessment of total Bp
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pose was to investigate the complete set of Bp antigenic proteins using
antisera generated in response to Chinese whole-cell, vaccine-induced
immunity.
In the Zhu study, twice as many total immunogens were identiﬁed
for human sera compared with our human sera pool. The disparity
was possibly due to Bp strain differences and lower post-pertussis infec-
tion speciﬁc circulating Ab titer levels of the pooled human antisera
(caused by prior serum dilution) used in our study. Interestingly, irre-
spective of the subproteome extraction, protein enrichment, and
immunodetection methods used, OmpQ was the only protein pulled
down using both mouse and human antisera from all four Bp EMFs in
our study, as well as in Zhu's immunoproteomic examinations.
In conclusion, we used Ag–Ab afﬁnity capture technologies in con-
junction with MS to identify immunoreactive proteins in three recent
circulating Bp strains. The overall goals were to identify biomarkers
that could be evaluated for use in pertussis strain differentiation
and in clinical diagnostics, and to detect novel targets for design of
prevention and therapeutic strategies.
As a ﬁrst step in this qualitative proteomics study, we examined
the applicability of a gel-free direct enzymatic-treated Bp EMF surfa-
ceome analysis. Common and strain-speciﬁc surface expressed pro-
tein proﬁles compared to the current vaccine-producing T strain
were generated, suggesting that there may be subtle differences of
surface protein expression among Bp strains. Further characterization
of these differentially expressed proteins at the molecular level is
warranted; which may reveal minor changes that could have implica-
tions on virulence and pathogenesis.
Second, antibodies generated from pertussis interperitoneal mouse
inoculation were used to assess protein immunogenicity and revealed
the identiﬁcation of known and unknown Bp antigens using a stable
IP approach. A comprehensive proteomic examination and an in vivo
immunopotency assessment are further needed to validate these PIPs
as true biomarker and vaccine candidates. Also, reassessing the immu-
noproteome of our unique Bp strains by stable IP using several human
sera from active pertussis infected human patients will provide a
more consistent depiction of the pertussis immunoproteome. Addition-
ally, efforts to enhance novel immunogen discoverymay require immu-
nodepletion of known and highly abundant antigenic-speciﬁc antibody
populations, such as OmpQ and BrkA. Highly abundant antigenic pro-
teins would in essence generate a larger speciﬁc IgG antibody pool.
This larger antibody subset would have a greater chance of binding to
protein G-beads, which invariably could overshadow lower expressed
immunostimulatory proteins.
Nonetheless, the gel-free approach described here for immunopro-
teome identiﬁcation remains a fruitful alternative for antigen discovery.
And because this is a pilot study using a small number of temporally
limited and genetically diverse strains, future studies will entail using
the described methods to examine a larger set of epidemiologically sig-
niﬁcant strainswith these putative, novel candidates laying the founda-
tion for clinical diagnostic design and improved vaccine development,
leading to the ultimate prevention of this deadly infection.
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